Elmos Q2 2026: 15% H1 Sales Growth Is Forcing a Repricing-or Exposing FOMO

Elmos is now being judged on repeatability, not one strong quarter

After management raised its 2026 guidance in May, the company came back in August to say full-year guidance confirmed. That matters more than the headline growth rate on its own. One strong update can create hope; two clean confirmations build credibility.

The core argument is simple. H1 sales rose 15.4%, which suggests Elmos is not relying on a single lucky quarter. Bulls see a company executing across a full half-year. Bears will say the next quarter still has to hold up, but the burden has shifted: Elmos no longer needs to sound promising, because it has already produced another round of tangible proof.

H1 sales and margin strength point to real operating leverage

The first-half results are strong on both the top line and the profit mix. H1 sales reached €314.5 million, up 15.4% year over year. First-half operating EBIT rose to €75.8 million from €55.7 million a year earlier, and the operating EBIT margin reached 24.1% versus 20.4%.

The Q1 comparison shows this has been a pattern, not a one-quarter bounce. In Q1, Elmos already posted EBIT of €36.2 million on a 23.8% EBIT margin. The fact that profitability remained firm in H2 as well argues for a more durable operating improvement than a simple spring catch-up.

Cash generation is improving faster than most investors focus on

Profitability matters, but the market usually pays more for earnings that turn into cash without heavy reinvestment. Elmos is doing that. Adjusted free cash flow reached €55.5 million in the first half, up from €22.0 million, while capex remained light at €8.8 million, or 2.8% of sales.

That pattern also started in Q1, when Elmos generated adjusted free cash flow of €40.7 million, or 26.7% of sales, with capex at just 1.8% of sales. Two quarters of strong cash conversion matter because they suggest the recovery is not being financed by heavier investment.

What keeps the debate alive

The cautious case is not that Elmos had a good half-year. It is that investors may still be treating a recovery as something more permanent than it is. That is a fair debate. A credibility story only works if the company keeps backing it up.

From here, the key question is not whether Elmos can grow. It is whether the market is ready to assign a more durable multiple after management confirmed full-year guidance following an upgraded 2026 outlook. The next scheduled checkpoint is the quarterly result Q2/2026 on August 4, 2026. If demand, margins, or cash conversion stay firm, the rerating thesis gains force. If not, the stock remains more cyclical rebound than permanent growth premium.